152 related articles for article (PubMed ID: 38895891)
1. Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer.
Sukumar JS; Sardesai S; Ni A; Williams N; Johnson K; Quiroga D; Ramaswamy B; Wesolowski R; Cherian M; Stover DG; Gatti-Mays M; Pariser A; Sudheendra P; George MA; Lustberg M
Cancer Med; 2024 Jun; 13(12):e7317. PubMed ID: 38895891
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study.
Ferreira AR; Ribeiro J; Miranda A; Mayer A; Passos-Coelho JL; Brito M; Fernandes J; Gouveia J; Costa L; Vaz-Luis I
Clin Breast Cancer; 2019 Oct; 19(5):e654-e667. PubMed ID: 31327728
[TBL] [Abstract][Full Text] [Related]
4. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
5. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
[TBL] [Abstract][Full Text] [Related]
6. Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.
Yeo W; Ueno T; Lin CH; Liu Q; Lee KH; Leung R; Naito Y; Park YH; Im SA; Li H; Yap YS; Lu YS;
Breast Cancer Res Treat; 2019 Oct; 177(3):549-559. PubMed ID: 31270763
[TBL] [Abstract][Full Text] [Related]
7. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
Pagani O; Francis PA; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Di Leo A; Coates AS; Goldhirsch A; Gelber RD; Regan MM;
J Clin Oncol; 2020 Apr; 38(12):1293-1303. PubMed ID: 31618131
[TBL] [Abstract][Full Text] [Related]
8. OFS plus AI or SERM vs. SERM alone in premenopausal women with hormone receptor-positive breast cancer: a prospective cohort study using the real-world database.
Hu K; He P; Peng Q; Zhong X; Deng L; Xie Y; Li J; Xu H; Lu D; Zheng H
Breast Cancer; 2019 May; 26(3):339-348. PubMed ID: 30367358
[TBL] [Abstract][Full Text] [Related]
9. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen.
Meattini I; Livi L; Saieva C; Franceschini D; Scotti V; Mangoni M; Loi M; Di Brina L; Zei G; Bonomo P; Greto D; Gelain E; Nori J; Sanchez LJ; Orzalesi L; Bianchi S; Biti G
Clin Breast Cancer; 2013 Aug; 13(4):247-53. PubMed ID: 23684167
[TBL] [Abstract][Full Text] [Related]
11. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
[TBL] [Abstract][Full Text] [Related]
12. Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study.
Ferreira AR; Palha A; Correia L; Filipe P; Rodrigues V; Miranda A; André R; Fernandes J; Gouveia J; Passos-Coelho JL; Moreira A; Brito M; Ribeiro J; Metzger-Filho O; Lin NU; Costa L; Vaz-Luis I
Breast; 2018 Feb; 37():107-113. PubMed ID: 29131988
[TBL] [Abstract][Full Text] [Related]
13. HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
Bartlett JMS; Ahmed I; Regan MM; Sestak I; Mallon EA; Dell'Orto P; Thürlimann B; Seynaeve C; Putter H; Van de Velde CJH; Brookes CL; Forbes JF; Viale G; Cuzick J; Dowsett M; Rea DW;
Eur J Cancer; 2017 Jul; 79():129-138. PubMed ID: 28494403
[TBL] [Abstract][Full Text] [Related]
14. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
Conte B; Poggio F; Del Mastro L
Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
[TBL] [Abstract][Full Text] [Related]
15. Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B.
Marmé F; Martin M; Untch M; Thode C; Bonnefoi H; Kim SB; Bear H; Mc Carthy N; Gelmon K; García-Sáenz JA; Kelly CM; Reimer T; Valota O; Toi M; Rugo HS; Gnant M; Makris A; Bassy M; Zhang Z; Furlanetto J; Nekljudova V; Loibl S
ESMO Open; 2024 Jun; 9(6):103466. PubMed ID: 38838498
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer.
Figg WD; Cook K; Clarke R
Cancer Biol Ther; 2014; 15(12):1586-7. PubMed ID: 25535893
[TBL] [Abstract][Full Text] [Related]
17. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T
Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022
[TBL] [Abstract][Full Text] [Related]
18. Long-term comparisons of the efficacy, safety, and pregnancy outcomes of adjuvant tamoxifen plus ovarian function suppression in premenopausal Han and Zhuang Chinese patients with hormone receptor-positive early breast cancer.
Tang S; Zhang Q; Tang X; Chen D; Zhang F; Liu J; Wei W; Liu D
J Int Med Res; 2019 Feb; 47(2):641-652. PubMed ID: 30354917
[TBL] [Abstract][Full Text] [Related]
19. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Goel S; Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
[TBL] [Abstract][Full Text] [Related]
20. Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL).
Lee J; Im SA; Kim GM; Jung KH; Kang SY; Park IH; Kim JH; Ahn HK; Park YH
Cancer Res Treat; 2021 Jul; 53(3):695-702. PubMed ID: 33332933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
